Dynavax to Present at J.P. Morgan 35th Annual Heal
Post# of 617763
BERKELEY, CA --(Marketwired - January 09, 2017) - Dynavax Technologies Corporation (
The live or replayed versions of the webcast will be available by visiting the "Investors" section of the Dynavax website or may be reached directly at: http://jpmorgan.metameetings.com/confbook/hea...nk?p=22909 .
About Dynavax Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious diseases and oncology. Dynavax's lead product candidates are SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies, HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine, and DV-281, an investigational immunotherapy for lung cancer, for which Phase 1 studies will be initiated in 2017. For more information, visit www.dynavax.com .
Contact: Michael Ostrach Chief Financial Officer 510-665-7257 Email contact
(0)
(0)